American Century Companies Inc. Sells 11,999 Shares of United Therapeutics Co. (NASDAQ:UTHR)

American Century Companies Inc. lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 23.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,152 shares of the biotechnology company's stock after selling 11,999 shares during the period. American Century Companies Inc. owned 0.09% of United Therapeutics worth $13,462,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC purchased a new stake in United Therapeutics during the 4th quarter valued at $67,000. MassMutual Private Wealth & Trust FSB boosted its holdings in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in shares of United Therapeutics by 678.9% in the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of United Therapeutics during the fourth quarter valued at approximately $131,000. 94.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 72,500 shares of company stock valued at $26,134,500 over the last 90 days. 11.90% of the stock is owned by company insiders.

Remove Ads

United Therapeutics Stock Performance

NASDAQ UTHR traded down $14.90 during mid-day trading on Friday, reaching $292.46. 579,460 shares of the stock were exchanged, compared to its average volume of 450,601. United Therapeutics Co. has a 1-year low of $230.39 and a 1-year high of $417.82. The business's fifty day simple moving average is $333.78 and its 200 day simple moving average is $354.54. The stock has a market capitalization of $13.13 billion, a PE ratio of 12.84, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter in the previous year, the firm posted $4.36 earnings per share. On average, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the topic of a number of research reports. HC Wainwright restated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.